204 related articles for article (PubMed ID: 28622390)
21. Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation.
Benencia F; Courrèges MC; Fraser NW; Coukos G
Cancer Biol Ther; 2008 Aug; 7(8):1194-205. PubMed ID: 18458533
[TBL] [Abstract][Full Text] [Related]
22. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
[TBL] [Abstract][Full Text] [Related]
24. COTA (colon-ovarian tumor antigen). An immunohistochemical study.
Pant KD; Fenoglio-Preiser CM; Berry CO; Zamora PO; Ram MD; Fulks RM; Rhodes BA
Am J Clin Pathol; 1986 Jul; 86(1):1-9. PubMed ID: 3524190
[TBL] [Abstract][Full Text] [Related]
25. Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers.
Williams LH; Choong D; Johnson SA; Campbell IG
Clin Cancer Res; 2006 Dec; 12(23):6967-72. PubMed ID: 17145815
[TBL] [Abstract][Full Text] [Related]
26. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets.
Scanlan MJ; Welt S; Gordon CM; Chen YT; Gure AO; Stockert E; Jungbluth AA; Ritter G; Jäger D; Jäger E; Knuth A; Old LJ
Cancer Res; 2002 Jul; 62(14):4041-7. PubMed ID: 12124339
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic inactivation of TMS1/ASC in ovarian cancer.
Terasawa K; Sagae S; Toyota M; Tsukada K; Ogi K; Satoh A; Mita H; Imai K; Tokino T; Kudo R
Clin Cancer Res; 2004 Mar; 10(6):2000-6. PubMed ID: 15041718
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Turner TB; Meza-Perez S; Londoño A; Katre A; Peabody JE; Smith HJ; Forero A; Norian LA; Straughn JM; Buchsbaum DJ; Randall TD; Arend RC
Oncotarget; 2017 Jul; 8(27):44159-44170. PubMed ID: 28498806
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells.
Cho CY; Wang JH; Chang HC; Chang CK; Hung WC
J Cell Physiol; 2007 Oct; 213(1):65-9. PubMed ID: 17443689
[TBL] [Abstract][Full Text] [Related]
30. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
[TBL] [Abstract][Full Text] [Related]
31. A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer.
Mori Y; Cai K; Cheng Y; Wang S; Paun B; Hamilton JP; Jin Z; Sato F; Berki AT; Kan T; Ito T; Mantzur C; Abraham JM; Meltzer SJ
Gastroenterology; 2006 Sep; 131(3):797-808. PubMed ID: 16952549
[TBL] [Abstract][Full Text] [Related]
32. Cause and consequence of cancer/testis antigen activation in cancer.
Whitehurst AW
Annu Rev Pharmacol Toxicol; 2014; 54():251-72. PubMed ID: 24160706
[TBL] [Abstract][Full Text] [Related]
33. Expression patterns of cancer testis antigens in testicular germ cell tumors and adjacent testicular tissue.
Yuasa T; Okamoto K; Kawakami T; Mishina M; Ogawa O; Okada Y
J Urol; 2001 May; 165(5):1790-4. PubMed ID: 11342977
[TBL] [Abstract][Full Text] [Related]
34. Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers.
Eng KH; Tsuji T
PLoS One; 2014; 9(11):e111586. PubMed ID: 25380171
[TBL] [Abstract][Full Text] [Related]
35. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines.
Imura M; Yamashita S; Cai LY; Furuta J; Wakabayashi M; Yasugi T; Ushijima T
Cancer Lett; 2006 Sep; 241(2):213-20. PubMed ID: 16303245
[TBL] [Abstract][Full Text] [Related]
36. Immunization using male germ cells and gametes as rich sources of cancer/testis antigens for inhibition of 4T1 breast tumors' growth and metastasis in BALB/c mice.
Safavi A; Kefayat A; Ghahremani F; Mahdevar E; Moshtaghian J
Int Immunopharmacol; 2019 Sep; 74():105719. PubMed ID: 31272065
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.
Stone ML; Chiappinelli KB; Li H; Murphy LM; Travers ME; Topper MJ; Mathios D; Lim M; Shih IM; Wang TL; Hung CF; Bhargava V; Wiehagen KR; Cowley GS; Bachman KE; Strick R; Strissel PL; Baylin SB; Zahnow CA
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10981-E10990. PubMed ID: 29203668
[TBL] [Abstract][Full Text] [Related]
38. β-Catenin gene promoter hypermethylation by reactive oxygen species correlates with the migratory and invasive potentials of colon cancer cells.
Banskota S; Dahal S; Kwon E; Kim DY; Kim JA
Cell Oncol (Dordr); 2018 Oct; 41(5):569-580. PubMed ID: 29923144
[TBL] [Abstract][Full Text] [Related]
39. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy.
Karpf AR
Epigenetics; 2006; 1(3):116-20. PubMed ID: 17786175
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a common antigen of colorectal and mucinous ovarian tumors, COTA.
Pant KD; Zamora PO; Rhodes BA; Sachatello CR; Hagihara PF; Griffen WO; van Nagell JR; Fulks R; Ram MD
Tumour Biol; 1984; 5(5):243-54. PubMed ID: 6442455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
